Targeting the RAF/MEK/ERK, PI3K/AKT and p53 pathways in hematopoietic drug resistance

Adv Enzyme Regul. 2007:47:64-103. doi: 10.1016/j.advenzreg.2006.12.013. Epub 2007 Mar 26.
No abstract available

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Antineoplastic Agents / pharmacology*
  • Cell Line, Tumor
  • Drug Delivery Systems* / methods
  • Drug Resistance, Neoplasm / physiology*
  • Extracellular Signal-Regulated MAP Kinases / antagonists & inhibitors
  • Extracellular Signal-Regulated MAP Kinases / biosynthesis
  • Extracellular Signal-Regulated MAP Kinases / genetics
  • Hematologic Neoplasms / drug therapy*
  • Hematologic Neoplasms / enzymology
  • Hematologic Neoplasms / metabolism
  • Mice
  • Mitogen-Activated Protein Kinase Kinases / antagonists & inhibitors
  • Mitogen-Activated Protein Kinase Kinases / biosynthesis
  • Mitogen-Activated Protein Kinase Kinases / genetics
  • Phosphatidylinositol 3-Kinases / biosynthesis
  • Phosphatidylinositol 3-Kinases / genetics
  • Phosphoinositide-3 Kinase Inhibitors
  • Proto-Oncogene Proteins c-akt / antagonists & inhibitors
  • Proto-Oncogene Proteins c-akt / biosynthesis
  • Proto-Oncogene Proteins c-akt / genetics
  • Signal Transduction / drug effects*
  • Signal Transduction / physiology
  • Tumor Suppressor Protein p53 / antagonists & inhibitors
  • Tumor Suppressor Protein p53 / biosynthesis
  • Tumor Suppressor Protein p53 / genetics
  • raf Kinases / antagonists & inhibitors*
  • raf Kinases / biosynthesis
  • raf Kinases / genetics
  • raf Kinases / metabolism

Substances

  • Antineoplastic Agents
  • Phosphoinositide-3 Kinase Inhibitors
  • Tumor Suppressor Protein p53
  • Proto-Oncogene Proteins c-akt
  • raf Kinases
  • Extracellular Signal-Regulated MAP Kinases
  • Mitogen-Activated Protein Kinase Kinases